Study of a Tiotropium Inhaler For Shortness of Breath in Advanced Non-Small Cell Lung Cancer (TIDAL)

H

Hamilton Health Sciences (HHS)

Status and phase

Unknown
Phase 2

Conditions

Dyspnea
NSCLC

Treatments

Drug: Placebo
Drug: Tiotropium

Study type

Interventional

Funder types

Other

Identifiers

NCT01172925
2009-TIDAL

Details and patient eligibility

About

The feeling of shortness of breath is very common in lung cancer. It is uncomfortable for patients and upsetting for their family. Although drugs like morphine and oxygen can help some patients feel better, they don't help everybody, and they are not used in patients with early symptoms. More relief is needed for these patients. The investigators are studying a drug called tiotropium, which is used in emphysema. It is an inhaler that opens the airways to allow easier breathing. Every patient will get the drug but also a placebo, in a random (flip of a coin) order. They will get each for 2 weeks. The investigators will see if they feel better with the drug.

Enrollment

34 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Histologically or cytologically proven incurable stage IIIb or stage IV non-small cell lung cancer.
  2. Dyspnea as defined by a score of 2 or higher on the 10-point Dyspnea Numeric Scale (Appendix 2).
  3. New dyspnea or worsening dyspnea within the last 6 months per patient reporting.

Exclusion criteria

  1. Age < 18.

  2. An FEV1 / FVC ratio < 0.7 with an FEV1 of < 80% predicted post-bronchodilator.

  3. Life expectancy < 3 months.

  4. Significant worsening of dyspnea over the last week such that an acute cardiac or respiratory condition is considered likely (e.g. pneumonia, heart failure).

  5. Myocardial infarction within the previous month.

  6. Heart rate ≥ 120.

  7. Active tuberculosis or tuberculosis receiving antibiotic therapy.

  8. Current or previous use of ipratropium, tiotropium, or oxitropium (see Appendix 6).

  9. Sensitivity to atropine.

  10. Pre-existing diagnosis of asthma or moderate to severe Chronic Obstructive Pulmonary Disease

  11. Use of beta-adrenergic bronchodilators more than once per week.

  12. Use of experimental therapy with known cholinergic or adrenergic effects.

  13. Uncontrolled glaucoma.

  14. Urinary retention.

  15. An active upper or lower respiratory infection or having taken antibiotics for any recent respiratory infection within 4 weeks.

  16. Symptomatic pleural or pericardial effusion.

  17. Evidence of reversible proximal endobronchial obstruction.

  18. Oxygen saturation < 90%.

  19. A hemoglobin of < 100 g/litre. Testing is to be within 4 weeks of randomization.

  20. Calculated or urine creatinine clearance ≤ 50 mL/min (see Appendix 5 for calculation). Testing it to be within 4 weeks of randomization.

  21. Weight loss > 10% of usual body weight within 6 months.

  22. Known pregnancy or lactating.

  23. Unable to independently fill out quality of life forms or give informed consent.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Quadruple Blind

34 participants in 2 patient groups, including a placebo group

Tiotropium
Experimental group
Description:
Inhaler
Treatment:
Drug: Tiotropium
Placebo
Placebo Comparator group
Description:
Inhaler
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Central trial contact

Sherry McFarlan, RN; John Goffin, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems